Avid Bioservices Inc (CDMO)

[Protector]

entdoc, I am puzzled.

my take-away from the cc: dawning realization in the executive suite that the Bavi PIII was a pipe dream from the beginning in terms of a home-run for Bavi as a giant (advanced lung cancer) killer, either alone or in chemo-combo.

I respect your take but the conclusions related to it cannot be drawn because the data says otherwise.

1) Breast PII showed Bavi worked with chemo
2) Breast IST with Stopeck showed Bavi works with chemo
3) 1st ln NSCLC showed Bavi worked with chemo (had also CTRL arm problem)
4) 2nd ln NSCLC showed Bavi work VERY GOOD with chemo after combining arms
5) idem after savaging showed that Bavi works EXTREMELY good with chemo
6) SUNRISE showed that Bavi worked as expected with chemo
7) Pancreatic showed Bavi worked with chemo (+2 weeks) with bad ECOG randomizing 1 to 3 against Bavi arm in one of the most difficult to treat and aggressive cancers.

ATTENTION: I am NOT pleading to continue CHEMO+BAVI even when it works, I can see the strategic advantage not too. We have the data and those years of track have certainly brought us were we need to be given the changed landscape with I-O. We have a SAFE drug that works with chemo but seems to have a bigger economical value with another category in which it seems to work even better according of what we see or hear from Brekken, MSK, NCCN and publications such as the one in Nature. So a switch to I-O now with faster approval paths such as BTD will not delay us more then a year if PPHM goes I-O and does not try to do it alone and will in the end bring us more revenue.

Holding the OUTPERFORMANCE of a 2 decade old chemo drug, docetaxel, in the control arm AGAINST Bavi to claim it does not work is unfair.

There are hundreds of thousands of patients treated with Docetaxel and the survival median is between 8 and 10 months. Period. That Doce now suddenly, abnormally and exceptionally DRAMATICALLY outperfomrs this MAXIMUM of 10 months (PLUS a marging that PPHM pro-actively added) so that Bavituximab must now SUDDENLY beat that OUTPERFORMANCE by two month and makes the trial stop CANNOT be part of any conclusion that Bavi didn't work and that SUNRISE is a pipe dream.

I'll leave it to that.